Share of Clicks for top 10 US Pharma & Biotech Research and Development brands
Here are the Top 10 competitors in the industry by Share of Clicks for the last month.
| Domain | Share of clicks |
|---|---|
| lilly.com | 28.84 |
| abbvie.com | 10.13 |
| gsk.com | 7.15 |
| pfizerforall.com | 6.43 |
| bms.com | 4.55 |
| sequencing.com | 3.38 |
| joinfridays.com | 3.25 |
| ro.co | 2.96 |
| regeneron.com | 2.6 |
| merck.com | 2.03 |
| others | 28.68 |
- lilly.com - 28.84%
- abbvie.com - 10.13%
- gsk.com - 7.15%
- pfizerforall.com - 6.43%
- bms.com - 4.55%
- sequencing.com - 3.38%
- joinfridays.com - 3.25%
- ro.co - 2.96%
- regeneron.com - 2.6%
- merck.com - 2.03%
- others - 28.68%
Copyright © Adthena. All rights reserved.
In the PPC landscape, lilly.com leads with 28.84% click share, closely followed by ‘others’ at 28.68%. Abbvie.com holds 10.13%, while gsk.com captures 7.15%.
Share of Spend for the top 10 US Pharma & Biotech Research and Development brands
Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.
| Date | pfizerforall.com | lilly.com | ro.co | joinfridays.com | tecvayli.com | abbvie.com | evenity.com | myriad.com | wegovy.com | gsk.com |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/03/01 | 18.13% | 31.24% | 0.17% | 0.93% | 2.12% | 4.16% | 1.94% | 3.12% | 0.11% | 2.25% |
| 2026/03/02 | 21.15% | 19.29% | 1.26% | 0% | 1.69% | 2.86% | 1.77% | 3.75% | 0.12% | 1.63% |
| 2026/03/03 | 15.89% | 37.08% | 0.8% | 0.02% | 1.36% | 0.08% | 1.38% | 3.03% | 0.1% | 1.28% |
| 2026/03/04 | 18.61% | 34.3% | 1.86% | 0.31% | 1.88% | 2.21% | 2.11% | 2.16% | 1.89% | 0.72% |
| 2026/03/05 | 13.08% | 36.37% | 1.02% | 0.6% | 2.32% | 1.81% | 1.23% | 2.99% | 0.19% | 1.84% |
| 2026/03/06 | 17.78% | 30.68% | 4.88% | 0.09% | 2.22% | 2.04% | 0.37% | 2.52% | 1.86% | 1.64% |
| 2026/03/07 | 18.12% | 22.73% | 3.87% | 5.07% | 2.87% | 4.32% | 0.5% | 1.65% | 1.79% | 1.87% |
| 2026/03/08 | 19.63% | 24.56% | 4.01% | 0.13% | 3.04% | 2.1% | 2.27% | 1.78% | 2.19% | 2.42% |
| 2026/03/09 | 19.22% | 22.53% | 5.53% | 6.92% | 2.77% | 1.09% | 1.26% | 2.19% | 1.66% | 1.15% |
| 2026/03/10 | 17.48% | 17.83% | 6.03% | 4.33% | 1.09% | 1% | 1.02% | 1.88% | 8.44% | 1.19% |
| 2026/03/11 | 19.56% | 28.19% | 0.66% | 2.02% | 1.25% | 1.93% | 1.57% | 1.49% | 2.33% | 1.58% |
| 2026/03/12 | 15.17% | 27.55% | 2.64% | 2.12% | 1.68% | 2.83% | 1.71% | 1.19% | 4.42% | 1.22% |
| 2026/03/13 | 13.83% | 32.32% | 7.98% | 3.63% | 1.15% | 1.35% | 1.4% | 0.89% | 2.44% | 0.72% |
| 2026/03/14 | 14.36% | 27.28% | 8.28% | 6.43% | 2.33% | 1.35% | 1.77% | 0.96% | 2.98% | 1.88% |
| 2026/03/15 | 12.07% | 26.63% | 6.04% | 6.63% | 2.12% | 3.5% | 1.72% | 0.94% | 1.43% | 1.19% |
| 2026/03/16 | 12.61% | 22.38% | 12.24% | 2.2% | 1.52% | 1.94% | 1.71% | 1.81% | 1.78% | 1.11% |
| 2026/03/17 | 12.9% | 19.87% | 8.68% | 8.49% | 1.22% | 2.02% | 1.65% | 1.35% | 0.11% | 1.57% |
| 2026/03/18 | 9.97% | 24.86% | 10.64% | 5.48% | 1.42% | 1.99% | 2.38% | 0.53% | 2.67% | 1.63% |
| 2026/03/19 | 12.04% | 25.56% | 11.03% | 6.26% | 1.99% | 2.45% | 1.37% | 0.87% | 2.65% | 1.15% |
| 2026/03/20 | 12.62% | 26.86% | 9.15% | 6.2% | 1.72% | 1.69% | 1.8% | 0.79% | 0.06% | 1.17% |
| 2026/03/21 | 12.03% | 30.22% | 7.4% | 3.92% | 1.12% | 5.79% | 1.48% | 0.95% | 2.7% | 1.62% |
| 2026/03/22 | 12.21% | 29.97% | 5.78% | 7.62% | 1.52% | 5.68% | 0.62% | 0.91% | 1.14% | 1.65% |
| 2026/03/23 | 15.15% | 25.75% | 4.16% | 2.56% | 2.25% | 2.65% | 2.07% | 1.2% | 1.44% | 2.15% |
| 2026/03/24 | 16.48% | 27.05% | 7.13% | 2.88% | 3.11% | 1.43% | 1.97% | 1.21% | 1.79% | 0.86% |
| 2026/03/25 | 10.8% | 25.96% | 9.91% | 3.86% | 1.48% | 1.21% | 1.46% | 0.23% | 4.23% | 1.2% |
| 2026/03/26 | 15.18% | 28.19% | 7.81% | 4.42% | 1.51% | 1.46% | 2.57% | 0.19% | 1.81% | 1.65% |
| 2026/03/27 | 12.34% | 25.68% | 10.88% | 3.42% | 2.64% | 2.66% | 3.19% | 0.58% | 2.33% | 1.34% |
| 2026/03/28 | 10.8% | 31.09% | 8.88% | 6.03% | 2.73% | 2.8% | 0.6% | 0.22% | 0.01% | 1.23% |
| 2026/03/29 | 19.19% | 9.79% | 10.6% | 4.85% | 3.25% | 8.92% | 1.34% | 0.99% | 1.8% | 2.76% |
| 2026/03/30 | 22.18% | 12.81% | 12% | 1.89% | 3.53% | 2.92% | 1.86% | 0.76% | 0.01% | 0.78% |
| 2026/03/31 | 19.98% | 19.72% | 10.98% | 6.32% | 2.52% | 2.15% | 1.49% | 1.41% | 1.37% | 0.76% |
- pfizerforall.com
- lilly.com
- ro.co
- joinfridays.com
- tecvayli.com
- abbvie.com
- evenity.com
- myriad.com
- wegovy.com
- gsk.com
Copyright © Adthena. All rights reserved.
Pfizerforall.com saw fluctuating trends, ending March strong at 19.98%. Lilly.com led early, peaking at 37.08%, but dipped to 19.72%. Ro.co’s steady rise concluded at 10.98%. Joinfridays.com and others showed varied patterns.
Competitor Count for US Pharma & Biotech Research and Development
Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.
| Date | Competitor Count |
|---|---|
| 2026/03/01 | 441 |
| 2026/03/02 | 443 |
| 2026/03/03 | 437 |
| 2026/03/04 | 437 |
| 2026/03/05 | 440 |
| 2026/03/06 | 450 |
| 2026/03/07 | 453 |
| 2026/03/08 | 446 |
| 2026/03/09 | 457 |
| 2026/03/10 | 455 |
| 2026/03/11 | 459 |
| 2026/03/12 | 450 |
| 2026/03/13 | 450 |
| 2026/03/14 | 443 |
| 2026/03/15 | 452 |
| 2026/03/16 | 459 |
| 2026/03/17 | 465 |
| 2026/03/18 | 468 |
| 2026/03/19 | 467 |
| 2026/03/20 | 466 |
| 2026/03/21 | 460 |
| 2026/03/22 | 458 |
| 2026/03/23 | 472 |
| 2026/03/24 | 449 |
| 2026/03/25 | 456 |
| 2026/03/26 | 430 |
| 2026/03/27 | 442 |
| 2026/03/28 | 429 |
| 2026/03/29 | 411 |
| 2026/03/30 | 427 |
| 2026/03/31 | 412 |
Copyright © Adthena. All rights reserved.
March began with 441 advertisers, peaking at 472 mid-month. A decline followed, ending at 412.
